What are the indications for Semaglutide Tablets?

Semaglutide tablets (Rybelsus) , as a new type of therapeutic drug, its indications are mainly focused on the treatment of type 2 diabetes. This drug effectively lowers the user's blood sugar level through multiple mechanisms such as stimulating insulin secretion, inhibiting glucagon secretion, and suppressing appetite.

First of all, semaglutide tablets are suitable for adult patients with type 2 diabetes who receive metformin and/or sulfonylureas on the basis of diet control and exercise but whose blood sugar is still poorly controlled. Such patients are often able to better control their blood sugar levels and reduce the risk of diabetes-related complications after adding semaglutide tablets.

Secondly, the drug is also suitable for reducing the risk of major cardiovascular adverse events, such as cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, in adults with type 2 diabetes and associated cardiovascular disease. The establishment of this indication is based on the fact that while semaglutide lowers blood sugar, it also exhibits a protective effect on the cardiovascular system.

In addition, when using semaglutide tablets, special attention needs to be paid to the patient's individual situation. For example, patients who are allergic to drug ingredients, pregnant women, and patients with a history or family history of medullary thyroid cancer should avoid using this drug. At the same time, if you experience any discomfort during medication, you should inform your doctor immediately and take appropriate measures according to the doctor's advice.

In general, semaglutide tablets are mainly suitable for the treatment of adultsType 2 diabetes and have shown potential in reducing the risk of cardiovascular disease. However, specific use needs to be determined based on the patient's specific situation and the guidance of the doctor. If you want to learn more about oral semaglutide, it is recommended to consult a professional overseas medical consultant.